The role of myelin in neurodegeneration: implications for drug targets and neuroprotection strategies

Title
The role of myelin in neurodegeneration: implications for drug targets and neuroprotection strategies
Publication Date
2024-04-05
Author(s)
Parrilla, Gabriella E
Gupta, Vivek
Vander Wall, Roshana
Salkar, Akanksha
Basavarajappa, Devaraj
Mirzaei, Mehdi
Chitranshi, Nitin
( author )
OrcID: https://orcid.org/0000-0002-6508-9865
Email: nchitran@une.edu.au
UNE Id une-id:nchitran
Graham, Stuart L
You, Yuyi
Type of document
Journal Article
Language
en
Entity Type
Publication
Publisher
Walter de Gruyter GmbH
Place of publication
Germany
DOI
10.1515/revneuro-2023-0081
UNE publication id
une:1959.11/71664
Abstract

Myelination of axons in the central nervous system offers numerous advantages, including decreased energy expenditure for signal transmission and enhanced signal speed. The myelin sheaths surrounding an axon consist of a multi-layered membrane that is formed by oligodendrocytes, while specific glycoproteins and lipids play various roles in this formation process. As beneficial as myelin can be, its dysregulation and degeneration can prove detrimental. Inflammation, oxidative stress, and changes in cellular metabolism and the extracellular matrix can lead to demyelination of these axons. These factors are hallmark characteristics of certain demyelinating diseases including multiple sclerosis. The effects of demyelination are also implicated in primary degeneration in diseases such as glaucoma and Alzheimer’s disease, as well as in processes of secondary degeneration. This reveals a relationship between myelin and secondary processes of neurodegeneration, including resultant degeneration following traumatic injury and transsynaptic degeneration. The role of myelin in primary and secondary degeneration is also of interest in the exploration of strategies and targets for remyelination, including the use of anti-inflammatory molecules or nanoparticles to deliver drugs. Although the use of these methods in animal models of diseases have shown to be effective in promoting remyelination, very few clinical trials in patients have met primary end points. This may be due to shortcomings or considerations that are not met while designing a clinical trial that targets remyelination. Potential solutions include diversifying disease targets and requiring concomitant interventions to promote rehabilitation.

Link
Citation
Reviews in the Neurosciences, 35(3), p. 271-292
ISSN
2191-0200
0334-1763
Start page
271
End page
292
Rights
Attribution 4.0 International

Files:

NameSizeformatDescriptionLink